Want to see TIL full AI Analyst Report?
TIL Stock Chart & Stats
$8.03
-$1.87(-8.00%)
At close: 4:00 PM EST
$8.03
-$1.87(-8.00%)
Day’s Range― - ―
52-Week Range$5.67 - $33.83
Previous CloseN/A
Volume80.17K
Average Volume (3M)27.56K
Market Cap
$50.86M
Enterprise Value$131.43M
Total Cash (Recent Filing)$74.57M
Total Debt (Recent Filing)$85.19M
Price to Earnings (P/E)―
Beta4.94
Next Earnings
Aug 07, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.08
Shares Outstanding6,781,976
10 Day Avg. Volume20,573
30 Day Avg. Volume27,563
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)0.64
Price to Sales (P/S)0.00
P/FCF Ratio-2.00
Enterprise Value/Market Cap2.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.48K
Enterprise Value/Ebitda-3.16
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.61
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash CushionReported cash balance provides a downside cushion, creating a cash-backed floor that can absorb operating losses while strategic options are explored.
Reduced Cash BurnReported cash suggests cash burn should contract materially, which lowers pressure on reserves and extends the company’s financial runway for pursuing options.
Strategic Alternatives OpportunityManagement evaluation of strategic alternatives positions the company as a cash-backed option that could gain value from a sale, license, or partnership of remaining assets.
Bears Say
Financing And Dilution RiskWith no clear catalysts to support a re-rating, continued cash burn could necessitate new financing, creating dilution risk that would further pressure the stock.
Lead Program TerminationDiscontinuation of AXN-2510 removes the company's primary value driver and forces a full reset of the investment thesis by erasing the core clinical narrative.
Pipeline Valuation ResetLoss of the lead asset effectively resets pipeline value toward zero, leaving the equity reliant largely on cash rather than future product revenue potential.
Instil Bio News
TIL FAQ
What was Instil Bio, Inc.’s price range in the past 12 months?
Instil Bio, Inc. lowest stock price was $5.67 and its highest was $33.83 in the past 12 months.
What is Instil Bio, Inc.’s market cap?
Instil Bio, Inc.’s market cap is $50.86M.
When is Instil Bio, Inc.’s upcoming earnings report date?
Instil Bio, Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 38 days.
How were Instil Bio, Inc.’s earnings last quarter?
Instil Bio, Inc. released its earnings results on May 15, 2026. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.59 by -$0.03.
Is Instil Bio, Inc. overvalued?
According to Wall Street analysts Instil Bio, Inc.’s price is currently Overvalued.
Does Instil Bio, Inc. pay dividends?
Instil Bio, Inc. does not currently pay dividends.
What is Instil Bio, Inc.’s EPS estimate?
Instil Bio, Inc.’s EPS estimate is -0.35.
How many shares outstanding does Instil Bio, Inc. have?
Instil Bio, Inc. has 6,781,976 shares outstanding.
What happened to Instil Bio, Inc.’s price movement after its last earnings report?
Instil Bio, Inc. reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.59. Following the earnings report the stock price went up 0.311%.
Which hedge fund is a major shareholder of Instil Bio, Inc.?
Currently, no hedge funds are holding shares in TIL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Instil Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Increased
By 5.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 7.9%
Last 30 Days ▼ 7.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.21%
12-Months-Change
Fundamentals
Return on Equity
-39.76%
Trailing 12-Months
Asset Growth
-15.59%
Trailing 12-Months
Company Description
Instil Bio, Inc.
Instil Bio, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating its efforts on devising novel therapeutic options for individuals battling cancer. A cornerstone of their research involves the advancement of autologous tumor-infiltrating lymphocyte (TIL) cell therapies. Their developmental portfolio features ITIL-168, currently under investigation for a range of malignancies including melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer. Another promising candidate, ITIL-306, is engineered to identify folate receptor alpha (FOLR1) and is being explored for gynecological cancers, non-small cell lung cancer, renal cancer, and other conditions. This company was founded in 2018 and has its principal office situated in Dallas, Texas.
Technical Analysis
Zentalis Pharmaceuticals
―
Nkarta
―
ALX Oncology Holdings
―
Surrozen
―
TScan Therapeutics
―
Ownership Overview
― Insiders
5.16% Mutual Funds
23.39% Other Institutional Investors
68.70% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---